STERIS
Infection Prevention Technologies

April 10, 2020

To Our Valued Customers:

The SARS-CoV-2 Coronavirus pandemic has created unprecedented challenges for patient care and staff safety. As your partner for infection prevention, we have been working with regulators to try to find solutions to your most pressing needs.

The FDA has granted STERIS an Emergency Use Authorization. This allows STERIS to temporarily provide a distinct option to effectively decontaminate compatible N95 or N95-equivalent Respirators **up to 10 times** using the **Non Lumen Cycle of the V-PRO® Low Temperature Sterilization System** (Models: maX and maX 2).

Testing demonstrated effective decontamination of compatible N95 or N95-equivalent respirators inoculated with a surrogate virus that is more resistant than SARS-CoV-2 Coronavirus. Studies also demonstrated that reprocessing does not impact the function of the respirators or alter the materials of construction.

To help navigate Healthcare Customers through this process, STERIS has created a COVID-19 landing page which includes all required information on how to prepare the respirators for decontamination in the aforementioned V-PRO® Low Temperature Sterilization Systems.

General information is also included on STERIS modalities related to SARS-CoV-2 Coronavirus.

STERIS remains committed to your success in delivering patient care through this pandemic. Thank you for all that you are doing to serve patients.

Best Regards,

STERIS
Infection Prevention Technologies